Novartis Inc header image

Novartis Inc

NOVN

Equity

ISIN CH0012005267 / Valor 1200526

SIX Swiss Exchange (2026-09-25)

CHF 119.48+0.44%

Novartis Inc
UMushroom community rating:

3.95 45 votes No rating yet

NegativeNeutralPositive

About company

Novartis Inc. is a global healthcare company that specializes in the development and distribution of innovative medicines. With a focus on addressing unmet medical needs, Novartis aims to improve and extend the lives of people suffering from serious diseases. The company operates in several core therapeutic areas, including cardiovascular, renal and metabolic diseases, immunology, neuroscience, and oncology. Novartis is known for its commitment to research and development, leveraging advanced technology platforms to create groundbreaking therapies. With a workforce of approximately 78,000 employees representing over 140 nationalities, Novartis has a significant global presence, reaching more than 284 million patients worldwide. The company's strategy revolves around delivering high-value medicines and employing novel access approaches to alleviate some of society's most significant disease burdens.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

21.6%1Y

36.5%3Y

63.1%5Y

Performance

20.5%1Y

19.4%3Y

18.8%5Y

Volatility

272926 M

Market cap (USD)

3,316,969

Daily traded volume (Shares)

88.82 / 87.81

1 day high/low (USD)

0.00 / 0.00

52 weeks high/low (USD)

01 January, 2022

Dividend ex-date

0.00

Dividend (USD)

0.00%

Dividend yield (p.a.)

0.002022

0.002023

0.002024

Est dividend (USD)

0.00%2022

0.00%2023

0.00%2024

Est dividend yield

10.00

P/E ratio

00.002022

00.002023

00.002024

Est P/E ratio

0.00

EPS (USD)

0.002022

0.002023

0.002024

Est EPS (USD)

Ratings & reviews

3.95

45 votes

Performance:

3.58

Innovation:

3.92

Society:

3.88

Nature:

3.43

Oliver Frei

Switzerland, 21 Mar 2026

-

Pavle Stojicic

Switzerland, 20 Mar 2026

Great company, wrong year to expect excitement. Own it in 2027 when the patent cliff is behind them and the new drugs are fully ramping.

Lorenzo Castillejo

Switzerland, 19 Mar 2026

Amazing stock

EQUITIES OF THE SAME SECTOR

Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc Valor: 22860122

Annual Return

-50%0%+50%

Risk level

110

-0.74%USD 14.77

iRhythm Technologies Inc

iRhythm Technologies Inc Valor: 34117792

Annual Return

-50%0%+50%

Risk level

110

-0.85%USD 110.80

Teva Pharmaceutical Industries Ltd

Teva Pharmaceutical Industries Ltd Valor: 758744

Annual Return

-50%0%+50%

Risk level

110

4.39%USD 38.72

Amylyx Pharmaceuticals Inc

Amylyx Pharmaceuticals Inc Valor: 115580129

Annual Return

-50%0%+50%

Risk level

110

-1.52%USD 30.14

Helen of Troy Ltd

Helen of Troy Ltd Valor: 938381

Annual Return

-50%0%+50%

Risk level

110

-0.61%USD 29.35

Faes Farma SA

Faes Farma SA Valor: 2837976

Annual Return

-50%0%+50%

Risk level

110

1.20%EUR 4.66

Tempus AI Inc

Tempus AI Inc Valor: 135855934

Annual Return

-50%0%+50%

Risk level

110

7.38%USD 82.24

Glaukos Corp

Glaukos Corp Valor: 28262610

Annual Return

-50%0%+50%

Risk level

110

0.91%USD 154.88

Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc Valor: 25419823

Annual Return

-50%0%+50%

Risk level

110

4.10%USD 38.06

Trupanion Inc

Trupanion Inc Valor: 24738737

Annual Return

-50%0%+50%

Risk level

110

-2.01%USD 22.42

SIX

FactSet

Clearbit

Logos provided by Clearbit